Expectations trend
FY2028 · fiscal year ending 2028-06-30 · fmp
ANEBULO PHARMACEUTICALS INC (ANEB)
OTCHealth CareBiotechnologySnapshot 2026-11-04
$0.260.00%
Close 2026-11-05 · 1-day change
OTCHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ANEB yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
maintain access to capital to fund operations | A supporting condition in ANEBULO PHARMACEUTICALS INC's published investment case. The stated target is secure at least one capital raise or credit facility within next 12 months. | Under Pressure | no capital access secured and liquidity deteriorates next 12 months | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-06-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making business case, not an established earnings compounder. The long-term thesis is in a watch state: management is described as stable, but recent financial performance is weak and overall risk is high.
The evidence snapshot gives no valuation or expectations data, so it is not possible to judge whether ANEB is cheap, fair, or expensive versus peers, or what the market already assumes. Loss-making status means conventional earnings-based valuation evidence is also absent here.
Recent performance sits well below its industry cohort, and the snapshot characterizes earnings quality as loss-making. The sector backdrop improved, but that does not resolve the company-specific weakness; the evidence also records a February notice concerning delisting or a continued listing rule.
The multi-year view hinges on whether company performance improves, but the snapshot provides little company-specific detail on execution or operating drivers. Near term, weaker jobs data could weigh on cyclical names, while continued strength or weakness among sector bellwethers could support or fade the Healthcare tailwind.
ANEB’s long-term thesis is uncertain: stable management and a better sector backdrop are outweighed by weak results, losses, high risk, and limited company-specific evidence. The thesis remains on watch. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
stabilize financial condition and avoid further delisting risks |
| The company aims to stabilize its financial condition and regain investor confidence. |
| Under Pressure |
| any new delisting notice or regulatory failure next 4 quarters |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
reduce losses and move toward profitability | A primary condition in ANEBULO PHARMACEUTICALS INC's published investment case. The stated target is reduce net losses by at least 20% YoY next fiscal year. | Broken | net losses do not improve or worsen next fiscal year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.49 → $-0.49 · observed estimates
$0.08B → $0.08B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-07-25 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-07-26 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-07-27 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-07-28 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-07-29 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-07-30 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-07-31 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-01 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-02 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-03 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-04 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-05 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-06 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-07 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-08 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-09 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-10 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-11 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-12 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-13 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-14 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-15 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-16 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-17 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-18 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-19 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-20 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-21 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-22 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-23 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-24 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-25 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-26 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-27 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-28 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-29 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-30 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-08-31 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-01 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-02 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-03 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-04 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-05 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-06 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-07 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-08 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-09 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-10 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-11 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-12 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-13 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-14 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-15 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-16 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-17 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-18 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-19 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-20 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-21 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-22 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-23 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-24 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-25 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-26 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-27 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-28 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-29 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-09-30 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-01 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-02 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-03 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-04 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-05 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-06 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-07 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-08 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-09 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-10 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-11 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-12 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-13 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-14 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-15 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-16 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-17 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-18 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-19 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-20 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-21 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-22 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-23 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-24 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-25 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-26 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-27 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-28 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-29 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-30 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-10-31 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-11-01 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-11-02 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-11-03 | $-0.49 | $78,754,000 | 1 / 1 |
| 2026-11-04 | $-0.49 | $78,754,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.